Vertex Pharmaceuticals (Vertex Pharmaceuticals) of the United States announced on April 18, local time, that it has made significant progress in developing the selective NAV1.8 inhibitor suzetrigine (VX-548). The project may become the first new drug used to treat acute and neurological pain in more than 20 years. According to the press release, the US Food and Drug Administration (FDA) agreed with Vertex to submit a new drug application (NDA) for the treatment of moderate to severe acute pain on a rolling basis by Vertex. Vertex has begun a rolling submission process and is expected to complete submissions in the second quarter of 2024. Recently, Suzetrigine was granted another breakthrough therapy by the FDA to treat DPN related pain.